| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 84 | — | 17.3x | Top tier | |
Growth | 32 | 4.4% | 7.1% | Bottom tier | |
Quality | 34 | 0.6% | 4.5% | Bottom tier | |
Safety | 48 | 4.0x | 2.6x | Around median | |
Capital Return | 91 | 2.65% | 0.06% | Top tier | |
Momentum | 95 | 69.0% | -1.6% | Top tier | |
Sentiment | 75 | 6 | 3 | Top tier |
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Viatris Inc. develops, manufactures, and markets a global portfolio that combines established branded medicines, generics, complex generics, complex injectables, transdermal drug delivery systems, and innovative medicines in development. Its business spans developed markets, emerging markets, the JANZ region, and Greater China, and its revenue benefits from products such as Breyna, Yupelri, Creon, and Brufen, as well as estradiol patches and octreotide and iron sucrose products, while it works to add Gwyn Lo and fast-acting meloxicam to its commercial portfolio.
In Q2 fiscal year 2026, revenue reached $3.8 billion, with operational growth of 3.5% year over year, while the news showed reported growth of 5%, and the company recorded a net loss under U.S. generally accepted accounting principles of $119 million. Adjusted earnings before interest, taxes, depreciation, and amortization reached $1.2 billion, adjusted earnings per share were $0.69, and the adjusted gross margin reached 57.5% after improving by approximately one percentage point due to the product mix in Greater China and North American generics.
The segment mix drove performance in Q2 fiscal year 2026; net sales rose 16% in Greater China, 2% in developed markets, 1% in North America, and 2% in Europe, while JANZ was approximately flat and emerging markets declined 2%. Within Greater China, e-commerce sales increased 36%, and this channel represented between 10% and 15% of the business there, while North America benefited from demand for estradiol patches and the strength of Breyna and complex injectables.
The analyst consensus on VTRS is Neutral, with an average price target of $21 and a narrow range between $20 and $22. The entire target range is above the 52-week range high of $18.39, compared with a low of $9.43, reflecting expectations of potential improvement but not eliminating the reported losses, Nashik disruptions, and competitive pressures. No usable earnings multiple is available within the provided data, while the valuation assessment remains tied to the company’s ability to convert growth in adjusted metrics into more stable reported profitability.
Figures in the text are as of 2026-08-29; the live price is shown at the top of the page.
Viatris revenue reached approximately $3.8 billion in Q2 fiscal year 2026, with operational growth of 3.5% year over year, while the news showed reported growth of 5%. The company recorded adjusted earnings before interest, taxes, depreciation, and amortization of $1.2 billion and adjusted earnings per share of $0.69. The adjusted gross margin reached 57.5%, but this coincided with a net loss under U.S. generally accepted accounting principles of $119 million.
Net sales in Greater China rose 16% in Q2 fiscal year 2026, supported by demand for cardiovascular products and established brands. E-commerce sales increased 36%, and this channel represented between 10% and 15% of the company’s business in Greater China. However, management expects growth to moderate during the second half of fiscal year 2026 due to a change in public hospital procurement policy and its implementation across 31 provinces.
Gwyn Lo received U.S. approval ahead of the targeted regulatory decision date and is a low-estrogen hormonal contraceptive patch used once weekly. Fast-acting meloxicam remained under U.S. Food and Drug Administration review during the August 6, 2026 call, and management estimated its potential at approximately $500 million in peak sales, subject to approval and the final label. The company is also targeting the submission of Nefecon in Japan by the end of 2026, while pitolisant applications for two indications were in the final stages of review.
Automated analysis for informational purposes only — not investment advice.
Viatris expects Phase 3 data readouts for both selatogrel and cenerimod in the first half of 2027. The selatogrel study was designed to measure a risk reduction of approximately 20%, while the company stated that a reduction of between 10% and 15% could represent an acceptable commercial threshold, and enrollment was progressing at a rate of approximately 1,200 patients per month. In the two cenerimod studies, the company exceeded its target for patients with elevated interferon-1 expression to represent approximately 70% of participants, with the primary endpoint measured after one year.
The company linked the disruptions to a fire in Q1 fiscal year 2026 and U.S. Food and Drug Administration inspection observations in May 2026. It estimated their impact on second-half fiscal year 2026 revenue at between $100 million and $150 million, with a greater impact in Q3 followed by expected moderation in Q4. The affected products are concentrated in low-margin oral generics in emerging markets and some European products, and no individual product generates more than $20 million in revenue.
Viatris generated free cash flow of $329 million in Q2 fiscal year 2026, rising to $449 million excluding transaction, restructuring, and tax costs. Through early August 2026, the company deployed approximately $1.4 billion of capital, including nearly $550 million returned to shareholders and approximately $270 million in share repurchases. It also repaid nearly $900 million of debt due in June 2026 and ended the quarter with a gross leverage ratio of approximately 2.9 times, with approximately $1.6 billion of deployable capital for the remainder of fiscal year 2026.